Next Article in Journal
Ablative and Immunostimulatory Effects of Histotripsy Ablation in a Murine Osteosarcoma Model
Previous Article in Journal
Effects of Tiliroside and Lisuride Co-Treatment on the PI3K/Akt Signal Pathway: Modulating Neuroinflammation and Apoptosis in Parkinson’s Disease
Previous Article in Special Issue
Delphi-Based Consensus on Interstitial Lung Disease Screening in Patients with Connective Tissue Diseases (Croatian National-Based Study)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 10
10.3390/biomedicines11102736
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Biomedicines 2021, 9(6), 650.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Štorkánová et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines 2021, 9, 650

by
Hana Štorkánová
1,2,
Lenka Štorkánová
1,
Adéla Navrátilová
1,2,
Viktor Bečvář
1,
Hana Hulejová
1,
Sabína Oreská
1,2,
Barbora Heřmánková
3,
Maja Špiritović
1,3,
Radim Bečvář
1,2,
Karel Pavelka
1,2,
Jiří Vencovský
1,2,
Jörg H. W. Distler
4,
Ladislav Šenolt
1,2 and
Michal Tomčík
1,2,*
1
Institute of Rheumatology, 12800 Prague, Czech Republic
2
Department of Rheumatology, First Faculty of Medicine, Charles University, 12800 Prague, Czech Republic
3
Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, 16252 Prague, Czech Republic
4
Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany
*
Author to whom correspondence should be addressed.
Biomedicines 2023, 11(10), 2736; https://doi.org/10.3390/biomedicines11102736
Submission received: 23 September 2023 / Accepted: 3 October 2023 / Published: 9 October 2023
(This article belongs to the Special Issue Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis)
Browse Figure
Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 4 as published. The representative picture of the immunohistochemistry staining for aSMA of the group entitled BLM (w1-6) + nintedanib (w4-6) was erroneously selected from a different group of mice. The corrected Figure 4 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Štorkánová, H.; Štorkánová, L.; Navrátilová, A.; Bečvář, V.; Hulejová, H.; Oreská, S.; Heřmánková, B.; Špiritović, M.; Bečvář, R.; Pavelka, K.; et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines 2021, 9, 650. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 11 02736 g001
Figure 4. Treatment with 17-DMAG prevents further progression and may induce regression of proliferation of myofibroblasts induced by bleomycin. (A) Representative images of α-smooth muscle actin (aSMA)-stained skin sections are shown. aSMA-positive cells are stained brown, nuclei are counterstained blue by hematoxylin. Original magnification ×400. (B) Treatment with 17-DMAG prevents further progression and induces regression of the proliferation of myofibroblasts induced by bleomycin. The extent of the protective effects of 17-DMAG is comparable to the effect of the treatment with nintedanib. Columns represent the mean, and whiskers represent the standard error of the mean. w, week; NaCl, sodium chloride; BLM, bleomycin; 17-DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (inhibitor of Heat shock protein 90); ns, not significant (p ≥ 0.05); n = 8 mice in each group.
Figure 4. Treatment with 17-DMAG prevents further progression and may induce regression of proliferation of myofibroblasts induced by bleomycin. (A) Representative images of α-smooth muscle actin (aSMA)-stained skin sections are shown. aSMA-positive cells are stained brown, nuclei are counterstained blue by hematoxylin. Original magnification ×400. (B) Treatment with 17-DMAG prevents further progression and induces regression of the proliferation of myofibroblasts induced by bleomycin. The extent of the protective effects of 17-DMAG is comparable to the effect of the treatment with nintedanib. Columns represent the mean, and whiskers represent the standard error of the mean. w, week; NaCl, sodium chloride; BLM, bleomycin; 17-DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (inhibitor of Heat shock protein 90); ns, not significant (p ≥ 0.05); n = 8 mice in each group.
Biomedicines 11 02736 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Štorkánová, H.; Štorkánová, L.; Navrátilová, A.; Bečvář, V.; Hulejová, H.; Oreská, S.; Heřmánková, B.; Špiritović, M.; Bečvář, R.; Pavelka, K.; et al. Correction: Štorkánová et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines 2021, 9, 650. Biomedicines 2023, 11, 2736. https://doi.org/10.3390/biomedicines11102736

AMA Style

Štorkánová H, Štorkánová L, Navrátilová A, Bečvář V, Hulejová H, Oreská S, Heřmánková B, Špiritović M, Bečvář R, Pavelka K, et al. Correction: Štorkánová et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines 2021, 9, 650. Biomedicines. 2023; 11(10):2736. https://doi.org/10.3390/biomedicines11102736

Chicago/Turabian Style

Štorkánová, Hana, Lenka Štorkánová, Adéla Navrátilová, Viktor Bečvář, Hana Hulejová, Sabína Oreská, Barbora Heřmánková, Maja Špiritović, Radim Bečvář, Karel Pavelka, and et al. 2023. "Correction: Štorkánová et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines 2021, 9, 650" Biomedicines 11, no. 10: 2736. https://doi.org/10.3390/biomedicines11102736

APA Style

Štorkánová, H., Štorkánová, L., Navrátilová, A., Bečvář, V., Hulejová, H., Oreská, S., Heřmánková, B., Špiritović, M., Bečvář, R., Pavelka, K., Vencovský, J., Distler, J. H. W., Šenolt, L., & Tomčík, M. (2023). Correction: Štorkánová et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines 2021, 9, 650. Biomedicines, 11(10), 2736. https://doi.org/10.3390/biomedicines11102736

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop